o:1170 Stepen oštećenja jetre kod neoadjuvantne terapije metastatskog kolorektalnog karcinoma The degree of liver damage in neoadjuvant treatmant of metastatic colorectal cancer : doctoral dissertation sr The study included 90 patients operated for colorectal cancer with liver metastases, divided into three groups. In the first group (G1) were patients who received FOLFOX IV neoadjuvant therapy, while in the second group (G2) biological agent bevacizumab was added to FOLFOX IV. The third group was the control group without chemotherapy. Biochemical parameters of metabolic syndrome (MS) and liver damage were followed. Liver steatosis and sinusoidal obstructive syndrome (SOS) were assesed by pathohystological examination. Steatosis liver injury in pathohystology was found in 56.7 % of patients in G1, 3.3 % in G2 and in 40% in the control group. Independent risk factors for degree of statosis were triglycerides, HDL and BMI. MS was present in 75% of patients in G1, which was significantly higher in comparison to G2 (27%). SOS was registered in 66.7 % in G2, 6.7 % in G1, while it was not registered in the control group. Independent risk factors for liver SOS were the following parameters of MS: triglycerides and HDL. Prilog: listovi 112-114 Datum odbrane: 26.09.2016. Citology, oncology, cancerology 1025594605 91552101 4281 91552100 1025594605 2016-12-06T09:36:59.053Z 45 no 46 mentor Vanja M. 1973- Pecić 2016 63 mentor Miroslav Stojanović 2016 114 listova 2533189 http://phaidrabg.bg.ac.rs/o:1170 no yes 4 2016-12-06T09:36:59.320Z 70 kolorektalni karcinom, metastaze u jetri, neoadjuvantna terapija colorectal cancer, liver metastasis, neoadjuvant therapy 616.348/.35-006.6-085.277:616.36(043.3) B 200 1738 18A05 18A0502 2016